中国临床药理学杂志Issue(3)：224-226,3.DOI:10.13699/j.cnki.1001-6821.2016.03.010
比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌的临床疗效及安全性评价
Clinical efficacy and safety of bicalutamide combine with goserelin in the treatment of advanced prostate cancer
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of bi-calutamide combine with goserelin in the treatment of advanced prostate cancer.Methods Fifty cases of advanced prostate cancer patients were randomly divided into treatment group (25 cases) and control group (25 cases).Treatment group was given oral bicalutamide 50 mg, qd +sub-cutaneous goserelin 3.6 mg, once 4 weeks, a monthly review of serum prostate-specific antigen ( PSA ) content , when the serum PSA <0.2 ng· mL-1, disabled two drugs, when PSA>4 ng· mL-1, begin a new round of treatment.Control group was given the continuous dosing , the same dosage and usage as the treatment group.The course of treatment for two groups was 12 months.Comparison of the clinical efficacy , serum PSA value and adverse drug reactions.Results After 6, 9, 12 months of treatment , the clinical efficacy of treatment group was significantly higher than that of control group (P<0.05).After 3, 6, 9, 12 months of treatment , the serum PSA value was significantly lower than that of before treatment ( P<0.05 ) , and there was no significant difference in serum PSA between the two groups at each time point ( P>0.05 ).The main adverse drug reactions of the two groups were the castration syndrome , blood vessel contraction , osteoporosis , and liver toxicity, and the incidence rate of adverse drug reactions were not statistically different between the two groups ( P>0.05 ).Conclusion The clinical efficacy of intermittent administration for bicalutamide combined with goserelin in the treatment of advanced prostate cancer was significantly better than the continuous dosing , without increasing the incidence of adverse drug reactions.关键词
比卡鲁胺/戈舍瑞林/前列腺癌/临床疗效/安全性Key words
bicalutamide/goserelin/prostate cancer/clinical efficacy/safety分类
医药卫生引用本文复制引用
庞宽,周泽光,黄英凡,刘成倍,徐伟..比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2016,(3):224-226,3.基金项目
2015年度第二批广西医药卫生计划基金资助项目 （）
